e-Mindfulness for Depression (MMW)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03922217 |
|
Recruitment Status :
Recruiting
First Posted : April 19, 2019
Last Update Posted : May 20, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Depression Mental Health Disorder | Device: Mindful My Way | Not Applicable |
The investigators will conduct a clinical trial using a smartphone app to collect data on depressive symptoms and cognitive function, and a website to deliver pre-recorded mindfulness sessions. The clinical trial will evaluate feasibility, acceptability, and efficacy with respect to depressive and cognitive symptoms, in a population of older adults at least 65 years of age with a current, active major depressive episode. This online, internet-delivered mindfulness meditation course is termed "Mindful My Way", consisting of 10 approximately one-hour classes consisting of mindfulness content (e.g., meditations) that a participant can watch on his or her computer or mobile device.
Assessment measures include a baseline diagnostic and screening assessment conducted by phone, plus:
- Pre-mindfulness and post-mindfulness : (a) (1) 4 weeks of cognitive testing delivered via app (brief game-like tests delivered up to 4 times daily); and (2) 4 weeks of depressive symptom surveys (8 depressive symptoms delivered 4 times daily) end of study, (b) a MADRS via phone interview (brief clinical interview of depressive symptom severity).
- During the mindfulness class: questions on participant preferences in order to evaluate the feasibility and acceptability of the mindfulness course, delivered via app.
All of these remote smartphone-based assessment techniques have been previously used in Wash U IRB-approved studies. (IRB # 201612089, IRB # 201709118).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 25 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | open label |
| Masking: | None (Open Label) |
| Masking Description: | open label |
| Primary Purpose: | Treatment |
| Official Title: | A Clinical Trial to Assess the Effect of Internet-delivered Mindfulness on Depressive Symptoms and Cognitive Function in Older Adults With Major Depression |
| Actual Study Start Date : | March 28, 2019 |
| Estimated Primary Completion Date : | March 5, 2021 |
| Estimated Study Completion Date : | March 5, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Mindfulness
This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
|
Device: Mindful My Way
Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
Other Name: MMW |
- EMA Depression Scale [ Time Frame: Change from baseline, established during the 4 weeks preceding the intervention, which will be measured in the 4 weeks following completion of the intervention ]Scale Range: 0-8 (0-no depressive symptoms; 8-worst depressive symptoms measurable with this scale)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 65 Years and older (Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females aged 65 or older
- DSM-V diagnosis of Major Depressive Disorder or Bipolar, Depressed type and experiencing depressive symptoms consistent with current major depressive episode
- Not currently psychotic and no history of psychosis within the previous 12 months; psychosis reported in the distant past may not be exclusionary if brief, per PI's judgment
- English speaking
- Able to give informed consent
- iOS smartphone user with internet access
- iOS operating system 6 or newer
- Internet access to view internet mindfulness course
Exclusion Criteria:
- Confirmed psychotic disorder, history of primary post-traumatic stress disorder
- Current or recent substance use disorder that according to the PI's judgement would confound the interpretation of the study results
- Any severe Axis II personality disorder or psychotic disorder that, in the PI's judgement, could confound diagnosis or adherence to treatment
- Meets DSM-V criteria for Mental Retardation
- Acutely suicidal or homicidal (i.e., in imminent danger with plan, urges and intent to harm oneself or others including any prior serious attempts (e.g., those requiring hospitalization) at the PI discretion
- Current incarceration
- Inability to cognitively manage the tasks required in this study
- Unstable medical condition (e.g. uncontrolled diabetes mellitus or hypertension)
- Concurrent cognitive training, such as brain-training software, regular engagement in mindfulness practice and/or yoga x) significant neurological condition (e.g. stroke, seizure disorder, multiple sclerosis), that in the PI's judgment, could confound the interpretation of study results
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03922217
| Contact: Aaron Mofsen, MD | 3143625154 | mofsena@wustl.edu | |
| Contact: Julie Schweiger | 3143625154 | schweigj@wustl.edu |
| United States, Missouri | |
| Washington University School of Medicine, Health Mind Lab | Recruiting |
| Saint Louis, Missouri, United States, 63108 | |
| Contact: Mary Stephens, BS 314-747-1134 m.stephens@wustl.edu | |
| Responsible Party: | Eric Lenze, Professor of Psychiatry, Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT03922217 |
| Other Study ID Numbers: |
201811036 |
| First Posted: | April 19, 2019 Key Record Dates |
| Last Update Posted: | May 20, 2020 |
| Last Verified: | May 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Depression Depressive Disorder Mental Disorders Behavioral Symptoms Mood Disorders |

